Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis
Giuseppina Augimeri, Maria E. Gonzalez, Alessandro Paolì, Ahmad Eido, Yehyun Choi, Boris Burman, Sabra Djomehri, Santhosh Kumar Karthikeyan, Sooryanarayana Varambally, Johanna M. Buschhaus, Yu-Chih Chen, Loredana Mauro, Daniela Bonofiglio, Alexey I. Nesvizhskii, Gary D. Luker, Sebastiano Andò, Euisik Yoon, Celina G. Kleer
Giuseppina Augimeri, Maria E. Gonzalez, Alessandro Paolì, Ahmad Eido, Yehyun Choi, Boris Burman, Sabra Djomehri, Santhosh Kumar Karthikeyan, Sooryanarayana Varambally, Johanna M. Buschhaus, Yu-Chih Chen, Loredana Mauro, Daniela Bonofiglio, Alexey I. Nesvizhskii, Gary D. Luker, Sebastiano Andò, Euisik Yoon, Celina G. Kleer
View: Text | PDF
Research Article Cell biology Oncology

A hybrid breast cancer/mesenchymal stem cell population enhances chemoresistance and metastasis

  • Text
  • PDF
Abstract

Patients with triple-negative breast cancer remain at risk for metastatic disease despite treatment. The acquisition of chemoresistance is a major cause of tumor relapse and death, but the mechanisms are far from understood. We have demonstrated that breast cancer cells (BCCs) can engulf mesenchymal stem/stromal cells (MSCs), leading to enhanced dissemination. Here, we show that clinical samples of primary invasive carcinoma and chemoresistant breast cancer metastasis contain a unique hybrid cancer cell population coexpressing pancytokeratin and the MSC marker fibroblast activation protein-α. We show that hybrid cells form in primary tumors and that they promote breast cancer metastasis and chemoresistance. Using single-cell microfluidics and in vivo models, we found that there are polyploid senescent cells within the hybrid cell population that contribute to metastatic dissemination. Our data reveal that Wnt Family Member 5A (WNT5A) plays a crucial role in supporting the chemoresistance properties of hybrid cells. Furthermore, we identified that WNT5A mediates hybrid cell formation through a phagocytosis-like mechanism that requires BCC-derived IL-6 and MSC-derived C-C Motif Chemokine Ligand 2. These findings reveal hybrid cell formation as a mechanism of chemoresistance and suggest that interrupting this mechanism may be a strategy in overcoming breast cancer drug resistance.

Authors

Giuseppina Augimeri, Maria E. Gonzalez, Alessandro Paolì, Ahmad Eido, Yehyun Choi, Boris Burman, Sabra Djomehri, Santhosh Kumar Karthikeyan, Sooryanarayana Varambally, Johanna M. Buschhaus, Yu-Chih Chen, Loredana Mauro, Daniela Bonofiglio, Alexey I. Nesvizhskii, Gary D. Luker, Sebastiano Andò, Euisik Yoon, Celina G. Kleer

×

Figure 6

WNT5A, IL-6, and CCL2 proteins are enriched in human chemoresistant metastatic breast carcinomas.

Options: View larger image (or click on image) Download as PowerPoint
WNT5A, IL-6, and CCL2 proteins are enriched in human chemoresistant meta...
(A) Differential expression analysis on the proteomics profile of metastatic and nonmetastatic human TNBC tumors (n = 4 per group). Volcano plots show differential up- and downregulated proteins. We considered all protein in the region P < 0.05 and fold change > 1 and outliers within P < 0.001 and between –1 < fold change < 1. (B) Protein network graph (STRING) depicts predicted protein-protein interaction networks of WNT5A, IL-6, and CCL2 with up- and downregulated proteins in A. Note formation of 2 nodes (red and green), STRING analysis, PPI enrichment P = 6.72 × 10–6. (C) GO analysis showing the significant biological processes of the WNT5A, IL-6, and CCL2 significantly predicted protein-protein interaction network in metastatic versus nonmetastatic TNBC. (D) Analyses of publicly available datasets containing treatment response information on 1,329 breast cancer patients treated with antracyclines (e.g., doxorubicin) or taxanes (e.g., paclitaxel) in relationship to relapse-free survival at 5 years after treatment. Shown are box plots (top) and corresponding ROC curves. KM Plotter (Kmplot.com) was used.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts